iCo Therapeutics Announces Third Quarter 2018 Financial Results And Corporate Update
November 29, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
November 29, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
November 15, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
October 23, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
October 2, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
September 6, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
August 29, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
July 16, 2018, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:
June 27, 2018, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:
June 20, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
May 30, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)